A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Jan 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

12 Dec 2023 Results of post hoc analysis (n=80 from studies NCT03548220 and NCT03853798) assessing the impact of PK deficiency on work or school performance and how treatment with mitapivat impacts this over time in these pts presented at the 65th American Society of Hematology Annual Meeting and Exposition
15 Jun 2023 Results assessing changes in Hb and hemolysis after mitapivat treatment in adult pts with PK deficiency and baseline Hb>10 g/dL who were not regularly transfused and enrolled in the DRIVE-PK and ACTIVATE/LTE of presented at the 28th Congress of the European Haematology Association
11 May 2023 According to an Agios Pharmaceuticals Media Release, Sub-Analysis data from this trial will be presented at the 2023 European Hematology Association (EHA) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com